Bristol-Myers Squibb Company Ce

CELG-RINYSEHealthcare● Active

$0.10

$-0.02(-16.85%)

Market Cap$203594379

P/E Ratio—

52W High$0.1229

52W Low$0.0997

Avg Volume38K

Open$0.10

Beta-0.54

Earnings Financials Revenue

Bristol-Myers Squibb Company Ce (CELG-RI) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

CELG-RI · earnings · updated Jun 8, 2026

Latest Earnings

Q2 FY2026Report Date: Apr 30, 2026

EPS Actual

$1.58

Est. $1.42 · +11.3%

Revenue

$11.49B

Est. $10.93B · +5.1%

Fiscal Period

Q2 FY2026

FY ends December

Report Date

Apr 30, 2026

After Market Close

▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak

CELG-RI reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$0.37

Rev. $0.36B

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$0.37

Rev. Est.$0.36B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q3 FY2026	Jul 30, 2026	$1.61	—	—	—	$11.70B	—
▲ Q2 FY2026	Apr 30, 2026	$1.42	$1.58	+11.3%	$11.49B	$10.93B	+5.1%
▲ Q1 FY2026	Feb 5, 2026	$1.23	$1.26	+2.4%	$12.50B	$12.28B	+1.8%
▼ Q4 FY2025	Oct 30, 2025	$1.52	$1.08	-28.9%	$12.22B	$11.85B	+3.1%
◌ Q3 FY2025	Jul 31, 2025	$1.09	—	—	$12.27B	$11.44B	+7.2%
▼ Q2 FY2025	Apr 24, 2025	$1.49	$1.21	-18.8%	$11.20B	$10.70B	+4.7%
◌ Q3 FY2023	Sep 30, 2023	—	—	—	$10.97B	—	—
◌ Q2 FY2023	Jun 30, 2023	—	—	—	$11.23B	—	—

Q3 FY2026

Jul 30, 2026

EPS Actual

—

EPS Est.

$1.61

EPS Surpr.

—

Revenue

—

Q2 FY2026

Apr 30, 2026Beat

EPS Actual

$1.58

EPS Est.

$1.42

EPS Surpr.

+11.3%

Revenue

$11.49B

Q1 FY2026

Feb 5, 2026Beat

EPS Actual

$1.26

EPS Est.

$1.23

EPS Surpr.

+2.4%

Revenue

$12.50B

Q4 FY2025

Oct 30, 2025Miss

EPS Actual

$1.08

EPS Est.

$1.52

EPS Surpr.

-28.9%

Revenue

$12.22B

Q3 FY2025

Jul 31, 2025

EPS Actual

—

EPS Est.

$1.09

EPS Surpr.

—

Revenue

$12.27B

Q2 FY2025

Apr 24, 2025Miss

EPS Actual

$1.21

EPS Est.

$1.49

EPS Surpr.

-18.8%

Revenue

$11.20B

Q3 FY2023

Sep 30, 2023

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

$10.97B

Q2 FY2023

Jun 30, 2023

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

$11.23B

Analyst Estimates

Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.

EPS Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2028	$1.32	$1.32	$1.32	1
Q3 FY2028	$1.26	$1.26	$1.26	1
Q2 FY2028	$1.31	$1.31	$1.31	1
Q1 FY2028	$1.21	$1.21	$1.21	1
Q4 FY2027	$1.55	$1.55	$1.55	1
Q3 FY2027	$1.53	$1.53	$1.53	1

Revenue Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2028	$10.2B	$10.2B	$10.2B	1
Q3 FY2028	$9.9B	$9.9B	$9.9B	1
Q2 FY2028	$10.2B	$10.2B	$10.2B	1
Q1 FY2028	$9.9B	$9.9B	$9.9B	1
Q4 FY2027	$12.1B	$12.1B	$12.1B	1
Q3 FY2027	$11.6B	$11.6B	$11.6B	1

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
▲ Q2 FY2026	Apr 30, 2026	+11.3%	$0.09	$0.08	-13.45%
▲ Q1 FY2026	Feb 5, 2026	+2.4%	$0.09	$0.09	-3.48%
▼ Q4 FY2025	Oct 30, 2025	-28.9%	$0.03	$0.03	+16.92%
▼ Q2 FY2025	Apr 24, 2025	-18.8%	$0.03	$0.03	+0.00%

Q2 FY2026-13.45%

Report Date

Apr 30, 2026

EPS Beat/Miss

+11.3%

Price Before

$0.09

Price After

$0.08

Q1 FY2026-3.48%

Report Date

Feb 5, 2026

EPS Beat/Miss

+2.4%

Price Before

$0.09

Price After

$0.09

Q4 FY2025+16.92%

Report Date

Oct 30, 2025

EPS Beat/Miss

-28.9%

Price Before

$0.03

Price After

$0.03

Q2 FY2025+0.00%

Report Date

Apr 24, 2025

EPS Beat/Miss

-18.8%

Price Before

$0.03

Price After

$0.03

Avg Beat Reaction-8.46%

Avg Miss Reaction+8.46%

Beat Rate2 / 4 quarters

Largest Move+16.92% (Q4 FY2025)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Bristol-Myers Squibb Company Ce (CELG-RI) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $1.58 — beating the analyst consensus of $1.42 by +11.3%. CELG-RI has beaten EPS estimates for 2 consecutive quarters. The next CELG-RI earnings date is expected around September 1, 2026.

Each quarter, investors track CELG-RI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CELG-RI revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

CELG-RI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

CELG-RI earnings · 5 questions

Bristol-Myers Squibb Company Ce's next earnings report is expected around September 1, 2026. CELG-RI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CELG-RI historically reports after market close (AMC).

CELG-RI earnings datewhen is CELG-RI earningsCELG-RI next earnings datewhen does CELG-RI report earningsCELG-RI earnings calendar

▸ Source: FMP · Bristol-Myers Squibb Company Ce SEC filings · US GAAP · Bristol-Myers Squibb Company Ce SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026